Study sample baseline characteristics at index admission for Clostridium difficile compared with all Truven hospital admission claims in 2011.

1. This dataset is a de-identified summary table of prevalence rates for vision and eye health data indicators from the 2016 MarketScan® Commercial Claims and Encounters Data (CCAE) is produced by Truven Health Analytics, a division of IBM Watson Health. The CCEA data contain a convenience sample of insurance claims information from person with employer-sponsored insurance and their dependents, including 43.6 million person years of data. Prevalence estimates are stratified by all available combinations of age group, gender, and state. Detailed information on VEHSS MarketScan analyses can be found on the VEHSS MarketScan webpage (cdc.gov/visionhealth/vehss/data/claims/marketscan.html). Information on available Medicare claims data can be found on the IBM MarketScan website (https://marketscan.truvenhealth.com). The VEHSS MarketScan summary dataset was last updated November 2019.

Polypharmacy is increasingly common in the United States, and contributes to the substantial burden of drug-related morbidity. Yet real-world polypharmacy patterns remain poorly characterized. We have counted the incidence of multi-drug combinations observed in four billion patient-months of outpatient prescription drug claims from 2007-2014 in the Truven Health MarketScan® Databases. Prescriptions are grouped into discrete windows of concomitant drug exposure, which are used to count exposure incidences for combinations of up to five drug ingredients or ATC drug classes. Among patients taking any prescription drug, half are exposed to two or more drugs, and 5% are exposed to 8 or more. The most common multi-drug combinations treat manifestations of metabolic syndrome. Patients are exposed to unique drug combinations in 10% of all exposure windows. Our analysis of multi-drug exposure incidences provides a detailed summary of polypharmacy in a large US cohort, which can prioritize common drug combinations for future safety and efficacy studies.

Baseline characteristics of HF patients stratified by ejection fraction class (HFrEF, < 0.45; or HFpEF, ≥ 0.45).

Multivariable predictors of CT use during an inpatient or ED visit with a first or second diagnosis of IBD.